Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 605-140-1 | CAS number: 158237-07-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- two-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 Jan - 26 Nov, 1996
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Version / remarks:
- adopted 26 May 1983
- Deviations:
- yes
- Remarks:
- sperm parameters not evaluated
- Qualifier:
- according to guideline
- Guideline:
- other: U.S. EPA (Pesticide Assessment Guidelines, Subdivision F, Hazard Evaluation: Humans and Domestic Animals, Series 83-4: "Reproductive and Fertility Effects"
- Version / remarks:
- November 1984
- Qualifier:
- according to guideline
- Guideline:
- other: "Guidance on Toxicology Study Data for Application of Agricultural Chemical Registration", Society of Agricultural Chemicals, Japan (MAFF Requirements)
- Version / remarks:
- 1985
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxo-4,5-dihydro-1H-1,2,3,4-tetrazole-1-carboxamide
- EC Number:
- 605-140-1
- Cas Number:
- 158237-07-1
- Molecular formula:
- C16H20ClN5O2
- IUPAC Name:
- 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxo-4,5-dihydro-1H-1,2,3,4-tetrazole-1-carboxamide
1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- ICO:WU (IOPS Cpb)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Wistar rats ICO:WU (IOPS Cpb), IFFA, Credo/France, Belgium
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: (P) 5 - 6 weeks; (F1) 4 weeks
- Weight at study initiation: (P) Males: 169 - 217 g; Females: 112 - 158 g
- Housing: individually in Type IIa Makrolon® cages during acclimatization period, females were housed individually in Typ III cages during the mating period; males were placed in the cages of the females overnight, Bedding: low-dust soft-wood shavings (Ssniff GmbH, Soest)
- Diet: Altromin® 1321 meal (Altromin GmbH Lage), ad libitum
- Water: tap water, ad libitum, analysis was performed
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 ± 2
- Humidity (%): 55 ± 5
- Air changes (per hr): 15 -20
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The test substance was blended (using a mixing granulator, Loedige, Paderborn) with Altromin® 1321 feed containing 1% peanut oil (DAB 10) to minimize dust formation (including feed of the control group). The amount of test substance was calculated on the basis of an assumed 100% content of the test substance.
DIET PREPARATION
- Rate of preparation of diet: once weekly
- Mixing appropriate amounts with: Altromin® 1321 containing 1% peanut oil
- Storage temperature of food: at room temperature
- Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: overnight
- Proof of pregnancy: vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy
- After 3 weeks of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: yes (F0 and F1 females found sperm-positive on the first day of pairing but get not pregnant were co-housed over one week with the same male. Females not found sperm positive during the regular mating period were co-housed three times with the same male.)
- After successful mating each pregnant female was caged: Inseminated females were not further co-housed. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical investigations on homogeneity and stability of the test compound in diet preparations were done prior to commencement of the study using samples from test mixtures. The test substance concentration within the feed was checked at regular intervals throughout the study (start of study, randomly each 3 month period, end of study). This was done by analyzing samples of the food mixes used. Per dose one sample of the food mixes was taken on the day the food was prepared, and another was taken after being kept under animal room conditions for the feeding period. All samples taken directly after diet preparation or at the end of the feeding period(s) were kept deep frozen (at temperatures of approximately -20°C) until examination. Reserve samples from each mixture were stored at least for 8 weeks at about -20°C. The analytical investigations proved that the test substance concentrations were in the specified concentrations ranges.
- Duration of treatment / exposure:
- P0 males and females: 12 weeks before mating
P0 males and females: up to 21 days during mating period
P0 females: about 22 days during pregnancy
P0 females: 28 days during lactation of F1 male and female litters, until weaning of F1 litters
P1 males and females: 10 weeks before mating (treatment up to an age of at least 14 weeks)
P1 males and females: up to 21 days during mating period
P1 females: about 22 days during pregnancy
P1 females: 28 days during lactation of F2 male and female litters up to an age of 4 weeks - Frequency of treatment:
- once weekly up to necropsy (in the diet, ad libitum)
- Details on study schedule:
- - P1 parental animals not mated until an age of 14 weeks
- Age at mating of the mated animals in the study: at least 14 weeks
Doses / concentrationsopen allclose all
- Dose / conc.:
- 20 ppm
- Remarks:
- corresponding to a mean test substance intake of (P0):
1.4 mg/kg bw/day (males)
1.8 mg/kg bw/day (females)
corresponding to a mean test substance intake of (P1):
1.6 mg/kg bw/day (males)
2.2 mg/kg bw/day (females)
- Dose / conc.:
- 300 ppm
- Remarks:
- corresponding to a mean test substance intake of (P0):
21.4 mg/kg bw/day (males)
28.1 mg/kg bw/day (females)
corresponding to a mean test substance intake of (P1):
25.0 mg/kg bw/day (males)
32.1 mg/kg bw/day (females)
- Dose / conc.:
- 1 800 ppm
- Remarks:
- corresponding to a mean test substance intake of (P0):
138.9 mg/kg bw/day (males)
204 mg/kg bw/day (females)
corresponding to a mean test substance intake of (P1):
201.8 mg/kg bw/day (males)
259.2 mg/kg bw/day (females)
- No. of animals per sex per dose:
- 30 P0 males and females
30 P1 males and females - Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: The dosages were selected on the basis of the results of a one-generation study (T1060122) in Wistar rats (strain ICO:WU (IOPS Cpb) IFFA Credo /France, Belgium) in which the test substance was administered to groups of 10 males and 10 females at concentrations of 0, 50, 400, and 3200 ppm in the diet using a four week premating period (Bayer (b), 1997). In this study dietary concentrations of up to 400 ppm of the test substance were tolerated without adverse effects. The body weights and mortality of the parent animals were not affected up to 3200 ppm. In the group of 3200 ppm F0 rats consumed more food than controls and some lactating dams were found to be aggressive when placed into a new cage. Additionally, enhanced liver weights and a toxicologically relevant inhibition of the cholinesterase in the brain (F0 females) were seen in the 3200 ppm group. No adverse effects on pups were seen up to 400 ppm. At 3200 ppm body weights and survival of pups were reduced.
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily (once daily on weekends and public holidays). In P0 and P1 parental animals a detailed evaluation of the general condition was made and recorded at the weekly during the premating periods, during gestation periods females were examined on day 0, 7, 14, 20, and during lactation on day 0, 4, 7, 11, 14, 21, and 28.
- Cage side observations checked in table 2 were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily (once daily on weekends and public holidays). In P0 and P1 parental animals a detailed evaluation of the general condition was made and recorded weekly during the premating periods. During gestation periods females were examined on day 0, 7, 14, 20, and during lactation on day 0, 4, 7, 11, 14, 21, and 28. Laboratory tests on blood samples were performed in week 9 (P0 and P1) on 10 randomly selected animals per sex and group. Cholinesterase in plasma and erythrocytes were taken in the morning from the retro-orbital venous plexus of non-fasted animals anaesthetized with ether. During terminal necropsies brain samples (left half) were taken and deep frozen to be used for determination of cholinesterase activity. Since collecting of brains must be done over several weeks individual values were entered online under the fictitious week 20 (P0) or week 21 and 23 (P1).
BODY WEIGHT: Yes
- Time schedule for examinations: at the start of the study, the male animals were weighed at weekly intervals up to week 21, and the female animals until week 11 (= end of premating period). After insemination had been established, the female animals were weighed on postcoital days 0, 7,14 and 20; and on days 0, 4, 7, 11, 14, 21 and 28 after birth of their pups. P0 and P1 animals were weighed on the date of necropsy to permit calculation of the relative organ weights.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE: No - Oestrous cyclicity (parental animals):
- Vaginal smears were taken daily during the two last weeks of premating period. Fifteen randomly selected P0 and P1 females per dose level were used. The vaginal smears were examined microscopically whether large serrated cells indicating estrus had occurred. Vaginal smears were evaluated to characterize the estrus cycle length and to determine if females were cycling properly.
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- yes, maximum of 8 pups/litter (4 sex/litter as nearly as possible); excess pups were raised to an age of four weeks and then necropsied
PARAMETERS EXAMINED
The following parameters were examined in F1 / F2 offspring: number and sex of pups (including those of dead pups), individual body weights, clinical signs, malformations
GROSS EXAMINATION OF DEAD PUPS: yes, unless autolysis or cannibalism rendered examination impossible, pups that were found dead at birth, that died during the course of lactation as well as those killed in moribund condition were macroscopically inspected after opening the body cavities, with particular attention being paid to the organs of reproduction. A lung flotation in tap water was performed during the necropsy of pups found dead on the day of the first litter inspection. This was done to determine whether pups had breathed at birth or not.
- Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: P0 males were killed after mating period.
- Maternal animals: All surviving animals, after weaning (28 days) of litters, animals that died or were killed in moribund condition during the study were necropsied and macroscopically examined.
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera. The following organs of of the P0/P1 generation were fixed for analysis: adrenals (only P1), liver, pituitary gland, urinary bladder (only P1), vagina, uterus, ovaries, oviducts, mammary gland with skin, coagulation glands, seminal vesicles, prostate, tattooed ears, testes, epididymides and all organs/organ specimen exhibiting macroscopic changes.
HISTOPATHOLOGY / ORGAN WEIGHTS
The following tissues and organs were weighed: brain, liver, testes and ovaries were weighed in P0 animals.
The following organs of the control and high dose groups of both, the P0- and P1- generation were examined microscopically: coagulation glands, epididymides, mammary gland area, ovaries, oviducts, pituitary gland, prostate gland, seminal vesicles, testes, uterus including cervix uteri and vagina. Ovaries, oviducts, uteri and vagina were investigated additionally in low- and mid-dose P0 females. The adrenal glands and urinary bladder were examined in all groups of the P1 generation. The liver and gross lesions were examined from all parent animals of all groups. Organ weight determinations of the brain, liver, testes and ovaries were done during the scheduled necropsy of P0 and P1 rats. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring not selected as parental animals and all F2 offspring were sacrificed at 28 days of age, pups selected for litter reduction as well as pups delivered after the additional mating procedures were killed on postpartum day 4.
- Unscheduled necopsies: unless autolysis or cannibalism rendered examination impossible, pups that were found dead at birth, that died during the course of lactation as well as those killed (with carbon dioxide) in moribund condition were macroscopically inspected after opening the body cavities, with particular attention being paid to the organs of reproduction.
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the thoracic and abdominal viscera and organs with macroscipically visible changes.
HISTOPATHOLOGY / ORGAN WEIGTHS
The following tissues of the first F1 and F2 males and females per litter (day 28 p.p.) were fixed for analyses: liver and organs/organ specimen of all pups with macroscipically changes. The body weights and the weights of brain, liver, spleen and thymus were determined at scheduled necropsy.
The following organs of the control and high dose groups of both, the F0- and F1- generation were examined microscopically: coagulation glands, epididymides, mammary gland area, ovaries, oviducts, pituitary gland, prostate gland, seminal vesicles, testes, uterus including cervix uteri and vagina. Ovaries, oviducts, uteri and vagina were investigated additionally in low- and mid-dose F0 females. The adrenal glands and urinary bladder were examined in all groups of the F1 generation. - Statistics:
- a. The Dunnett-Test in connection with a variance analysis was used for body weights of parent animals, organ weights of parent animals
b. A Kruskal-Wallis-Test with a Steel-Test was done on food consumption data
c. The U-Test was used for the evaluation of the pup weights, litter sizes, litter weights. The mean pup weight of each individual litter was used as a basis for calculation of the pup weight means of the dose groups. The litter size calculation was based on the number of female animals with live pups.
d. Fisher's exact probability test (two-tailed) at significance levels of a = 5 % and a 1 % was used for the evaluation of the insemination index (1), fertility index (1), gestation index (1), live birth index (1), viability index (1), lactation index (1)
e. The adjusted Welsh-Test was used for CHE-Data evaluation
(1) done if dose-related changes had occurred - Reproductive indices:
- Insemination index (%) = No. of sperm positive females*/No. of females co-housed with a male* x 100
Fertility index (%) = No. of pregnant females/No. of sperm positive females** x 100
Gestation index (%) = No. of females with live pups/No. of pregnant females x 100
* excluding additional matings (those cases where mating was repeated with
another male)
** including pregnant females that were not sperm positive
*** moribund pups died during the course of culling were not included
# calculations were done by using number of pups per group - Offspring viability indices:
- Live birth index (%)# = No. of live pups at birth/total No. of pups born x 100
Viability index (%)# = No. of live pups on day 4 pre-culling/No. of live pups born x 100
Lactation index (%)# = No. of live pups after three/four weeks/No. of live pups after four days (after culling)*** x100
# calculations were done by using number of pups per group
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No effects were observed on appearance, general conditions and behaviour of test animals up to the highest dose applied.
yes control and 300 ppm: loss of hair in one female (non adverse)
yes control: diarrhea in one female (non adverse)
Please refer to table 2 under "Any other information on results incl. tables". - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- yes
control: 1/30 female died on day 24 due to delivery problems (dam could not deliver their pups) (non-adverse)
20 ppm: 1/30 pregnant female had been found dead on day 11 of pregnancy with unknown cause of death (non-adverse)
300 ppm: 1/30 female died on day 28 of pregnancy due to delivery problems (dam could not deliver their pups) (non-adverse)
1800 ppm: no mortality occured
Please refer to table 2 under "Any other information on results incl. tables". - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No effects observed. The body weights of the male and female F0 animals receiving up to 1800 ppm did not differ significantly from those of the controls.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- yes 300 and 1800 ppm: females of the 300 and 1800 ppm groups consumed 12.1 to 32.7% more food per animal during the premating period than controls, respectively. Weekly group means were sgnificantly higher at several (300 ppm) or most (1800 ppm) time points during the premating period, as well as sporadically at 1800 ppm during pregnancy and lactation. The food intake (per animal and per body weight) of all treated males and of females receiving 20 ppm test substance was comparable with control data. Deviations to control data occurring in these groups are below 10%.
yes 1800 ppm: due to the increase in food consumption at 1800 ppm in females these rats had a somewhat higher test substance intake than that expected from the dosing factor.
The test substance intake in treated male and female groups up to 300 ppm roughly corresponded to the theoretical dose intervals. Please refer to table 2 under "Any other information on results incl. tables". - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: toxicologically relevant cholinesterase inhibition was found in erythrocytes (30.9% in males and 40.3% in females) and the brain (39.1% in females only). Up to the dietary concentration of 300 ppm no biologically significant inhibition of cholinesterases was detected (adverse). Please refer to table 2 under "Any other information on results incl. tables".
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: increase in the number of rats exhibiting cytoplasmatic changes in hepatocytes. Additionally, centrilobular hypertrophy was found in 17/30 females. This effect is interpreted as a rather adaptive response due to substance intake and metabolism than as adverse effect (non-adverse). There were no treatment-related alterations of the liver morphology at a dose of 300 ppm. All other morphological findings are considered to be spontaneous in nature and within the normal range of background pathology commonly seen in rats of this strain and age. Please refer to table 2 under "Any other information on results incl. tables".
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- no effects observed
- Other effects:
- not examined
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- The mean of estrus cycle length and number of estri observed was comparable among the groups. Irregular estrus cycle and prolonged estrus was obersevd in individual females of all treatment groups without dose dependency and within the expected range of untreated animals. Thus this effect is considered as incidental and not treatment-related. Please refer to table 2 under "Any other information on results incl. tables".
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- The insemination, fertility, gestation and mean duration of pregnancy did not differ to a toxicologically relevant extent from the pertinent control data at levels of up to 1800 ppm (non adverse). Please refer to table 2 under "Any other information on results incl. tables".
Details on results (P0)
There were some F0 females (3-2-2-4 in ascending concentration) which got not pregnant with their first male. To investigate the reason of the failed pregnancy additional matings were performed with males already shown to be fertile (with another female). None of the three control and both 20 ppm females co-housed with a fertile male got pregnant. 1/2 300 ppm females delivered pups. In the 1800 ppm group 3/4 remated females dropped a litter and the remaining 1800 ppm female exhibited implantation sites in the uterus. In summary, results of regular and additional matings do not indicate any adverse effect on male or female fertility. The mating performance was not affected by the treatment at levels of up to 1800 ppm.
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOEL
- Remarks:
- general toxicity
- Effect level:
- 20 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed at this dose level
- Remarks on result:
- other:
- Remarks:
- 20 ppm corresponding to 1.8 mg/kg bw/day in females and 1.4 mg/kg bw/day in males
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed at this dose level
- Remarks on result:
- other:
- Remarks:
- 300 ppm corresponding to 28.1 mg/kg bw/day in females and 21.4 mg/kg bw/day in males
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- general toxicity
- Effect level:
- 1 800 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- histopathology: non-neoplastic
- Remarks on result:
- other: 1800 ppm corresponding to 138.9 mg/kg bw/day in males and 204 mg/kg bw/day in females
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- fertility
- Effect level:
- 1 800 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive function (oestrous cycle)
- reproductive performance
- Remarks on result:
- other: 1800 ppm corresponding to 138.9 mg/kg bw/day in males and 204 mg/kg bw/day in females
Target system / organ toxicity (P0)
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 800 ppm
- System:
- nervous system
- Organ:
- other: cholinesterase activity inhibited in erythrocytes and brain (Statistically significant inhibition by 20% or more in erythrocytes or brain is considered a clear adverse toxicological effect)
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Results: P1 (second parental generation)
General toxicity (P1)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No effects were observed on appearance and behaviour.
yes control, 20 and 300 ppm: loss of hair was observed in males and females of the control group, in one male of the 20 ppm group and in males and females of the 300 ppm group (non-adverse)
yes 20 ppm: one male with a poor general condition was observed (non-adverse)
yes 20 and 1800 ppm: at each dose level one animal showed agression (non-adverse)
For details, please refer to table 2 under "Any other information on results incl. tables". - Dermal irritation (if dermal study):
- not examined
- Description (incidence and severity):
- no data
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- None of the F1 males died unscheduled. In the 20 ppm (pregnant rat showed poor general condition) and 1800 ppm groups (rat showed aggressive behavior) each one female were killed prescheduled. No evidence of a treatment-related increase in mortality was observed (non-adverse). Please refer to table 2 under "Any other information on results incl. tables".
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: statistically significant body weight depression in both male and female weanlings with a maximum (26% and 15%) in week two. Additionally, pregnant and lactating females of this group exhibited reduced body weights. Please refer to table 2 under "Any other information on results incl. tables".
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: 12.0% (males) or 35.4% (females) higher food intake per rat was observed. Calculated per kg bw a 43.9% and 51.9% higher consumption was determined in males and females, respectively. Due to the increase in food consumption and lower body weights at 1800 ppm, males and females of this group had a somewhat higher test substance intake than that expected from the dosing factor. Please refer to table 2 under "Any other information on results incl. tables".
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: significant cholinesterase inhibition was found in erythrocytes (males 48.3% and females: 72.8%) and the brain (41.7% females) in P1 rats (adverse). Please refer to table 2 under "Any other information on results incl. tables".
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: absolute (12.7% in females) and relative (males: 6.6 and females 13.3%) liver weights were higher than in controls. This effect is interpreted as a rather adaptive response due to substance intake and metabolism than as adverse effect (non-adverse). Relative testes weight was also increased by about 12% in this group, since histopathological investigations revealed no morphological correlates and insemination index and fertility indices were not altered this finding is considered to have no toxicological relevance (non-adverse). All doses: ovary weights were sightly reduced in treated females without dose-response, reaching statistical significance at 20 and 300 ppm (non-adverse due to missing dose-response). Statistically significant lower absolute brain weight was observed. Statistically significant lower absolute brain weights were probably due to differences in body weight, which can differ more or less at the necropsy date due to weaning (non-treatment-related, non-adverse). Please refer to table 2 under "Any other information on results incl. tables".
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No significant gross pathological findings were observed at necropsy of male or female F1 animals at levels of up to 1800 ppm. Please refer to table 2 under "Any other information on results incl. tables".
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 300 and 1800 ppm: cytoplasmatic change (both sexes) and hypertrophy (females only) in the centrilobular hepatocytes were seen more often than at 0 or 20 ppm This effect is interpreted as a rather adaptive response due to substance intake and metabolism than as adverse effect (non-adverse). Additionally, a fine and even cytoplasmatic vacuolation of cortical cells in the zona fasciculata and glomerulosa, however, without signs of degenerative processes was found in the adrenal glands with increasing incidence in females receiving 300 or 1800 ppm (adverse).
yes 1800 ppm: in males the incidence of a simple urothelial hyperplasia in the urinary bladder was higher than in the other groups (adverse). All other findings recorded in the remaining organs are considered to be spontaneous in nature and within the normal range of the background pathology commonly seen in rats of this strain and age. Please refer to table 2 under "Any other information on results incl. tables". - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
Reproductive function / performance (P1)
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- The estrus cycle staging in F1 females showed no abnormalities up to 1800 ppm. Please refer to table 2 under "Any other information on results incl. tables".
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- The reproduction parameters such as mating performance, insemination, fertility, gestation as well as the mean duration of pregnancy showed no treatment-related effect at levels of up to 1800 ppm. There were two F1 females (1-1-0-0 with ascending dose) which had been found to be sperm-positive after the day of co-housing but failed pregnancy. According to experience this could have happened if a male co-housed with a female for the first time had inseminated the female outside the estrus. This assumption was supported by the fact that all these females had pups when remated with the same male for one week that followed the three week co-housing period. Please refer to table 2 under "Any other information on results incl. tables".
Effect levels (P1)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Effect level:
- 20 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: no adverse effects observed at this dose level
- Remarks on result:
- other: 20 ppm corresponding to 2.2 mg/kg bw/day in females and 1.6 mg/kg bw/day in males
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: no adverse effects observed at this dose level
- Remarks on result:
- other: 300 ppm corresponding to 32.1 mg/kg bw/day in females and 25 mg/kg bw/day in males
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- general toxicity
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical biochemistry
- organ weights and organ / body weight ratios
- histopathology: non-neoplastic
- Remarks on result:
- other: 300 ppm corresponding to 32.1 mg/kg bw/day in females and 25 mg/kg bw/day in males
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- general toxicity
- Effect level:
- 1 800 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical biochemistry
- organ weights and organ / body weight ratios
- histopathology: non-neoplastic
- Remarks on result:
- other: 1800 ppm corresponding to 259.2 mg/kg bw/day in females and 201.8 mg/kg bw/day in males
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- fertility
- Effect level:
- 1 800 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects on reproductive function/performance observed up to this dose level
- Remarks on result:
- other: 1800 ppm corresponding to 259.2 mg/kg bw/day in females and 201.8 mg/kg bw/day in males
Target system / organ toxicity (P1)
open allclose all
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 300 ppm
- System:
- endocrine system
- Organ:
- adrenal glands
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 800 ppm
- System:
- urinary
- Organ:
- bladder
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 800 ppm
- System:
- nervous system
- Organ:
- other: cholinesterase activity inhibited in erythrocytes and brain (Statistically significant inhibition by 20% or in erythrocytes or brain more is considered a clear adverse toxicological effect)
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No significant clinical findings were made in F1 pups during the four-week lactation period at levels of up to 1800 ppm. Please refer to table 2 under "Any other information on results incl. tables".
- Dermal irritation (if dermal study):
- no effects observed
- Description (incidence and severity):
- no data
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- PND 0: yes 1800 ppm: slightly more dead pups were found at birth resulting in a slightly reduced live birth index.
PND 4: mean viability indices were comparable among the groups up to and including 300 ppm. In the high-dose group, slightly fewer pups survived up to PND 4 (increased loss of pups as a result of cannibalism) resulting in a significantly reduced viability index of 82.1%. Please refer to table 2 under "Any other information on results incl. tables".
The total number of pups, litter size, and sex ratio did not differ to a toxicologically relevant extent from the pertinent control data at levels of up to 1800 ppm. Please refer to table 2 under "Any other information on results incl. tables". - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Birth weights were comparable among the test groups up to 1800 ppm; mean litter weight was significantly reduced on PND28 at 1800 ppm.
PND4 - PND28 : 1800 ppm: reduced pup weight in males (significant)
PND21 - PND28: 1800 ppm reduced pup weight in females (significant)
At the lower doses, sporadically, non-dose dependent altered pup weights were determined in males and females. Please refer to table 2 under "Any other information on results incl. tables". - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Please refer to P1 (second parental generation)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: liver weights were inconspicuous up to 300 ppm, but in relation to body weights they were increased (16-17%) at 1800 ppm in both sexes. This effect is interpreted as a rather adaptive response due to substance intake and metabolism than as adverse effect (non- adverse). Brain, spleen, and thymus weights of treated pups were not changed in a toxicologically relevant manner. Deviations occurring in some cases are minor and are considered to be a result of differences in body weights. Please refer to table 2 under "Any other information on results incl. tables".
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- In F1 pups necropsied during lactation period no macroscopical alterations due to the treatment were observed. No malformations were determined in the F1 pups, which died before PND 4, were killed in the process of litter reduction on PND 4, or were necropsied unscheduled during lactation at levels of up to 1800 ppm. No gross pathological findings were made in F1 weanlings at scheduled necropsy.
- Histopathological findings:
- not examined
- Description (incidence and severity):
- Please refer to P1 (second parental generation)
- Other effects:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no advers effects observed at this dose level
- Key result
- Dose descriptor:
- LOAEL
- Generation:
- F1
- Effect level:
- 1 800 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- viability
- mortality
- body weight and weight gain
- Remarks on result:
- other: correlated to maternal toxicity determined via cholinesterase inhibition
Results: F2 generation
General toxicity (F2)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No significant clinical findings were made in F2 pups during the four week lactation period at levels of up to 1800 ppm. Please refer to table 2 under "Any other information on results incl. tables".
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- yes 300 and 1800 ppm: the lactation indices were significantly reduced. The reduction observed at 300 ppm is not considered as treatment-related, since the indices were within the range of the control groups. The significantly reduced values at 1800 ppm are considered as treatment-related (adverse). Please refer to table 2 under "Any other information on results incl. tables".
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: reduced litter weights were visible at birth and weaning; individual birth weights were not affected up to 1800 ppm; mean body weights of male and female pups was statistically significantly depressed starting on PND 7; 300 ppm: increased mean body weight starting on PND 14 (adverse). Please refer to table 2 under "Any other information on results incl. tables".
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- yes 1800 ppm: 12% elevated liver weight means (relative) were noted in female pups. This effect is interpreted as a rather adaptive response due to substance intake and metabolism than as adverse effect (non- adverse). Reduced spleen weights (absolute about 18% and relative about 12%) were calculated in pups of both sexes. These effects are interpreted as related to reduced body weight gain and are therefore not considered as adverse. However, regarding the mean weights of the brain and thymus no conspicuous differences could be detected between the controls and treatment groups. Please refer to table 2 under "Any other information on results incl. tables".
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- In F2 pups necropsied during the lactation period no macroscopical alterations due to the treatment were observed. No malformations were determined in the F2 pups that had died before PND 4, were killed in the process of culling, or were necropsied unscheduled during lactation at levels of up to 1800 ppm. No gross pathological findings were made in F2 weanlings at scheduled necropsy.
- Histopathological findings:
- not examined
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Litter observations at birth:
Live birth indices and viability indices are comparable among the groups. No significant alteration in sex distribution was determined. At 1800 ppm, fewer pups were born resulting in a significantly reduced mean litter size.
Developmental neurotoxicity (F2)
- Behaviour (functional findings):
- not examined
- Description (incidence and severity):
- no data
Developmental immunotoxicity (F2)
- Developmental immunotoxicity:
- not examined
- Description (incidence and severity):
- no data
Effect levels (F2)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F2
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed up to this dose level
- Key result
- Dose descriptor:
- LOAEL
- Generation:
- F2
- Effect level:
- 1 800 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- other: reduced mean litter size; reduced lactation index
- Remarks on result:
- other: correlated to maternal toxicity determined via cholinesterase inhibition
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 1 800 ppm
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects as a secondary non-specific consequence of other toxic effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Any other information on results incl. tables
Table 1: Table for animal assignment for mating
|
Number of animals |
||||
Controls |
20 ppm |
300 ppm |
1800 ppm |
||
P0 |
1.4 mg/kg bw/day (males) 1.8 mg/kg bw/day (females)
|
21.4 mg/kg bw/day (males) 28.1 mg/kg bw/day (females)
|
138.9 mg/kg bw/day (males) 204.0 mg/kg bw/day (females)
|
||
P1 |
1.6 mg/kg bw/day (males) 2.2 mg/kg bw/day (females)
|
25 mg/kg bw/day (males) 32.1 mg/kg bw/day (females)
|
201.8 mg/kg bw/day (males) 259.2 mg/kg bw/day (females)
|
||
P0 |
m |
30 |
30 |
30 |
30 |
f |
30 |
30 |
30 |
30 |
|
P1 |
m |
30 |
30 |
30 |
30 |
f |
30 |
30 |
30 |
30 |
Table 2: Table for reproductive toxicity study
Parameter |
Generation |
Controls |
20 ppm |
300 ppm |
1800 ppm |
|
|||||||||||||||||||
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
|
|||||||||||||||||
Clinical Observations1)Incidence |
|
||||||||||||||||||||||||
appearance |
P0 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
||||||||||||||||
behaviour |
P0 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
||||||||||||||||
mortality |
P0 |
0/30 |
1/30 |
0/30 |
1/30 |
0/30 |
1/30 |
0/30 |
0/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
1/30 |
0/30 |
0/30 |
0/30 |
1/30 |
|
||||||||||||||||
loss of hair |
P0 |
/ |
1/30 |
/ |
0/30 |
/ |
1/30 |
/ |
0/30 |
|
|||||||||||||||
P1 |
2/30 |
1/30 |
0/30 |
1/30 |
2/30 |
5/30 |
0/30 |
0/30 |
|
||||||||||||||||
diarrhoea |
P0 |
/ |
1/30 |
/ |
0/30 |
/ |
0/30 |
/ |
1/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
1/30 |
|
||||||||||||||||
poor general condition |
P0 |
/ |
0/30 |
/ |
1/30 |
/ |
1/30 |
/ |
0/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
1/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
||||||||||||||||
aggression |
P0 |
/ |
0/30 |
/ |
0/30 |
/ |
0/30 |
/ |
0/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
1/30 |
0/30 |
0/30 |
0/30 |
1/30 |
|
||||||||||||||||
Mean daily food intake g/kg bw/day (premating period) |
P0 |
70.6 |
82.9 |
71.9 |
89.4 |
71.3 |
93.8 |
77.2 |
113.3 |
|
|||||||||||||||
P1 |
77.9 |
94.8 |
81.9 |
112.5 |
83.3 |
107.0 |
112.1 |
144.0 |
|
||||||||||||||||
Mean daily test substance intake mg/kg bw/day (premating period) |
P0 |
0 |
0 |
1.4 |
1.8 |
21.4 |
28.1 |
138.9 |
204.0 |
|
|||||||||||||||
P1 |
0 |
0 |
1.6 |
2.2 |
25.0 |
32.1 |
201.8 |
259.2 |
|
||||||||||||||||
Inhibition of Cholinesterases % plasma (week 9) |
P0 |
/ |
/ |
/ |
/ |
4.9 |
/ |
9.8 |
/ |
|
|||||||||||||||
P1 |
/ |
/ |
/ |
/ |
/ |
/ |
/ |
/ |
|
||||||||||||||||
Inhibition of Cholinesterases % erythrocytes (week 9) |
P0 |
/ |
/ |
/ |
/ |
/ |
/ |
30.9 |
40.3 |
|
|||||||||||||||
P1 |
/ |
/ |
/ |
/ |
2.3 |
16.3 |
48.3 |
72.8 |
|
||||||||||||||||
Inhibition of Cholinesterases % brain (terminal necropsy) |
P0 |
/ |
/ |
/ |
/ |
/ |
7.2 |
7.4 |
39.1 |
|
|||||||||||||||
P1 |
/ |
/ |
1.6 |
1.5 |
/ |
8.7 |
10.4 |
41.7 |
|
||||||||||||||||
Relative Organ weights [mg/100 g bw] brain |
P0 |
425 |
707 |
435 |
707 |
430 |
701 |
434 |
681 |
|
|||||||||||||||
P1 |
399 |
703 |
404 |
669 |
404 |
675 |
418 |
667 |
|
||||||||||||||||
liver |
P0 |
3558 |
3639 |
3471 |
3643 |
3469 |
3813 |
3804** |
4425** |
|
|||||||||||||||
P1 |
3430 |
4143 |
3409 |
4164 |
3403 |
4394 |
3658** |
4696** |
|
||||||||||||||||
testes/ovaries |
P0 |
709 |
64 |
721 |
64 |
741 |
63 |
765* |
62 |
|
|||||||||||||||
P1 |
717 |
62 |
735 |
54* |
744 |
52** |
806** |
58 |
|
||||||||||||||||
Absolut Organ weights [mg] brain |
P0 |
2050 |
1795 |
2058 |
1769 |
2023 |
1786 |
2018 |
1765 |
|
|||||||||||||||
P1 |
2008 |
1845 |
1986 |
1811 |
2023 |
1825 |
1916** |
1727** |
|
||||||||||||||||
liver |
P0 |
17234 |
9256 |
16482 |
9146 |
16405
|
9727 |
17773 |
11512** |
|
|||||||||||||||
P1 |
17378 |
10926 |
16862 |
11353 |
17140 |
11999 |
16893 |
12319* |
|
||||||||||||||||
testes/ovaries |
P0 |
3418 |
164 |
3401 |
160 |
3496 |
160 |
3557 |
160 |
|
|||||||||||||||
P1 |
3609 |
164 |
3626 |
145 |
3732 |
140* |
3707 |
150 |
|
||||||||||||||||
body weight [g] |
F0 |
484 |
255 |
474 |
251 |
473 |
255 |
467 |
260 |
|
|||||||||||||||
F1 |
506 |
264 |
495 |
272 |
503 |
273 |
462** |
261 |
|
||||||||||||||||
Histopathology Incidence |
|
||||||||||||||||||||||||
Centrilobular Hepatocytes: cytoplasmatic change
|
P0 |
0/30 |
0/30 |
0/30 |
1/30 |
0/30 |
0/30 |
15/30 |
21/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
0/30 |
8/30 |
4/30 |
21/30 |
23/30 |
|
||||||||||||||||
Centrilobular Hepatocytes: hypertrophy
|
P0 |
0/30 |
1/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
17/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
2/30 |
0/30 |
13/30 |
|
||||||||||||||||
Adrenal glands (cortex): cytoplasmatic vacuolation |
P0 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
|||||||||||||||
P1 |
0/30 |
0/30 |
0/30 |
1/30 |
0/30 |
5/30 |
0/30 |
28/30 |
|
||||||||||||||||
Urinary bladder: urothelial hyperplasia |
P0 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
|
|||||||||||||||
P1 |
1/30 |
0/30 |
0/30 |
0/30 |
0/30 |
0/30 |
3/30 |
1/30 |
|
||||||||||||||||
Reproductive Performance |
|
||||||||||||||||||||||||
|
|
Generation |
Controls |
20 ppm |
300 ppm |
1800 ppm |
|||||||||||||||||||
Insemination index |
% |
P0 |
100 |
100 |
96.7 |
96.7 |
|||||||||||||||||||
P1 |
100 |
100 |
100 |
100 |
|||||||||||||||||||||
Fertility index |
% |
P0 |
90 |
93.3 |
96.6 |
89.7 |
|||||||||||||||||||
P1 |
93.3 |
93.3 |
96.7 |
93.1 |
|||||||||||||||||||||
Gestation index |
% |
P0 |
96.7 |
96.4 |
96.4 |
100 |
|||||||||||||||||||
P1 |
100 |
100 |
93.1 |
100 |
|||||||||||||||||||||
females with irregular cycle/prolonged estrus
|
number |
P0 |
0 |
3 |
1 |
3 |
|||||||||||||||||||
|
P1 |
0 |
1 |
1 |
0 |
||||||||||||||||||||
Number of pups dead |
|
F1 |
0 |
3 |
0 |
10 |
|||||||||||||||||||
|
F2 |
2 |
2 |
3 |
2 |
||||||||||||||||||||
Live birth index |
% |
F1 |
100 |
98.9 |
100 |
96.3 |
|||||||||||||||||||
F2 |
99.1 |
99.3 |
99.0 |
99.2 |
|||||||||||||||||||||
Sex ratio |
% Males |
F1 |
50 |
50 |
46 |
52 |
|||||||||||||||||||
F2 |
45 |
46 |
53 |
49 |
|||||||||||||||||||||
Viability index |
% |
F1 |
97.3 |
96.5 |
94.3 |
82.1** |
|||||||||||||||||||
F2 |
96.8 |
96.5 |
98.6 |
97.7 |
|||||||||||||||||||||
Lactation index Day 28 |
% |
F1 |
77.9 |
80.3 |
77.7 |
78.1 |
|||||||||||||||||||
F2 |
95.0 |
90.6 |
88.2* |
73.6** |
|||||||||||||||||||||
Litter size (viable pups only) |
Mean |
P0 |
10.03 |
9.59 |
10.33 |
10.11 |
|||||||||||||||||||
P1 |
11.28 |
10.48 |
10.51 |
9.51** |
|||||||||||||||||||||
Litter weight Day 28 |
Mean [g] |
F1 |
485.50 |
434.98 |
460.59 |
381.80* |
|||||||||||||||||||
F2 |
567.47 |
508.17 |
538.72 |
383.89** |
|||||||||||||||||||||
Pub weight at birth
|
sex |
|
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
♂ |
♀ |
|||||||||||||||
day 0 |
Mean |
F1 |
6.4 |
5.95 |
6.26 |
5.94 |
6.30 |
6.19* |
6.34 |
5.98 |
|||||||||||||||
day 4 |
Mean |
F1 |
10.04 |
8.90 |
9.70 |
9.46 |
9.35 |
9.60* |
9.07** |
8.75 |
|||||||||||||||
day 7 |
Mean |
F1 |
15.18 |
13.64 |
13.50** |
13.91 |
13.75* |
14.51 |
12.96** |
12.95 |
|||||||||||||||
day 14 |
Mean |
F1 |
30.65 |
28.39 |
29.06 |
29.58 |
29.90 |
31.65** |
27.38** |
27.64 |
|||||||||||||||
day 21 |
Mean |
F1 |
49.55 |
46.18 |
47.51 |
46.87 |
48.02 |
49.51** |
41.71** |
41.59** |
|||||||||||||||
day 28 |
Mean |
F1 |
80.75 |
72.66 |
74.75** |
71.32 |
77.70 |
75.26 |
67.82** |
65.45** |
|||||||||||||||
day 0 |
Mean |
F2 |
6.35 |
6.01 |
6.25 |
6.06 |
6.34 |
5.95 |
6.44 |
6.26** |
|||||||||||||||
day 4 |
Mean |
F2 |
10.39 |
9.98 |
10.33 |
10.05 |
10.59 |
10.24 |
10.26 |
9.83 |
|||||||||||||||
day 7 |
Mean |
F2 |
16.31 |
15.75 |
15.44 |
15.03 |
16.80 |
15.74 |
14.24** |
14.17** |
|||||||||||||||
day 14 |
Mean |
F2 |
31.50 |
31.13 |
31.34 |
31.04 |
33.87** |
32.86* |
29.52** |
29.61** |
|||||||||||||||
day 21 |
Mean |
F2 |
48.19 |
47.61 |
50.11* |
48.75 |
51.80** |
49.96** |
43.51** |
43.40** |
|||||||||||||||
day 28 |
Mean |
F2 |
75.23 |
72.06 |
77.30 |
72.89 |
80.92** |
75.15** |
68.43** |
66.55** |
|||||||||||||||
F1 weanlings Relative Organ weights mg/100 g bw: brain |
|
F1 |
1826 |
1893 |
1897 |
1979 |
1812 |
1778 |
1992 |
2075 |
|||||||||||||||
liver |
|
F1 |
4112 |
3997 |
4008 |
3970 |
4208 |
4042 |
4813 |
4638 |
|||||||||||||||
spleen |
|
F1 |
328 |
344 |
331 |
316 |
344 |
324 |
323 |
319 |
|||||||||||||||
thymus |
|
F1 |
397 |
474 |
405 |
479 |
415 |
432 |
411 |
457 |
|||||||||||||||
body weight |
[g] |
F1 |
83 |
75 |
75 |
72 |
81 |
80 |
71 |
64 |
|||||||||||||||
F2 weanlings Relative Organ weights mg/100 g bw: brain |
|
F2 |
1891
|
1911 |
1811
|
1888 |
1664
|
1813 |
1938 |
1899 |
|||||||||||||||
liver |
|
F2 |
4461
|
4183
|
4048
|
4011
|
4263
|
4273
|
4639 |
4695 |
|||||||||||||||
spleen |
|
F2 |
315
|
322 |
318
|
303 |
320
|
309 |
277 |
280 |
|||||||||||||||
thymus |
|
F2 |
433
|
459 |
423
|
444 |
385
|
430 |
413 |
429 |
|||||||||||||||
body weight |
[g] |
F2 |
81 |
78 |
82 |
76 |
91 |
81 |
75 |
74 |
1)only effects occurring in more than one animal of the F0 or F1 generation are reported. Effects observed only in a single animal were not considered relevant.
Applicant's summary and conclusion
- Conclusions:
- CLP: not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.